Published in Front Biosci on May 01, 2002
Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest (2004) 1.37
Characterization of a permissive epitope insertion site in adenovirus hexon. J Virol (2006) 1.10
Substrate specificity of prostate-specific membrane antigen. Bioorg Med Chem (2007) 1.09
The molecular pruning of a phosphoramidate peptidomimetic inhibitor of prostate-specific membrane antigen. Bioorg Med Chem (2007) 1.08
High throughput T epitope mapping and vaccine development. J Biomed Biotechnol (2010) 1.04
In vitro targeted photodynamic therapy with a pyropheophorbide--a conjugated inhibitor of prostate-specific membrane antigen. Prostate (2009) 0.93
PSMA-targeted SPECT agents: mode of binding effect on in vitro performance. Prostate (2012) 0.91
Phosphoramidate derivatives of hydroxysteroids as inhibitors of prostate-specific membrane antigen. Bioorg Med Chem Lett (2007) 0.78
(177)Lu-Labeled Phosphoramidate-Based PSMA Inhibitors: The Effect of an Albumin Binder on Biodistribution and Therapeutic Efficacy in Prostate Tumor-Bearing Mice. Theranostics (2017) 0.75
Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med (2002) 4.04
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother (2007) 3.16
Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother (2002) 2.65
Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C. Head Neck (2009) 2.59
Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor. Cancer Res (2005) 1.44
Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer Res (2008) 1.41
The S100A10 subunit of the annexin A2 heterotetramer facilitates L2-mediated human papillomavirus infection. PLoS One (2012) 1.38
The Notch ligand Jagged-1 is able to induce maturation of monocyte-derived human dendritic cells. J Immunol (2002) 1.30
Ligation of CD137 receptor prevents and reverses established anergy of CD8+ cytolytic T lymphocytes in vivo. Blood (2003) 1.27
Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7. Clin Cancer Res (2007) 1.27
Mechanisms used by human papillomaviruses to escape the host immune response. Curr Cancer Drug Targets (2007) 1.26
The evolving field of human papillomavirus receptor research: a review of binding and entry. J Virol (2013) 1.20
Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization. Prostate (2009) 1.19
In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer. Cancer Res (2007) 1.16
Prostate stem cell antigen: a prospective therapeutic and diagnostic target. Cancer Lett (2008) 1.13
Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses. J Immunol (2002) 1.12
Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes. Vaccine (2004) 1.12
Identification of AKAP-4 as a new cancer/testis antigen for detection and immunotherapy of prostate cancer. Prostate (2011) 1.11
AKAP-4: a novel cancer testis antigen for multiple myeloma. Br J Haematol (2008) 1.11
Differential uptake and cross-presentation of human papillomavirus virus-like particles by dendritic cells and Langerhans cells. Cancer Res (2003) 1.11
Cancer testis antigens: novel biomarkers and targetable proteins for ovarian cancer. Int Rev Immunol (2011) 1.06
Human papillomavirus infection in head and neck cancer: the role of the secretory leukocyte protease inhibitor. Oncol Rep (2013) 1.06
Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions. Int J Cancer (2008) 1.06
A major role for the minor capsid protein of human papillomavirus type 16 in immune escape. J Immunol (2009) 1.05
Human papillomavirus can escape immune recognition through Langerhans cell phosphoinositide 3-kinase activation. J Immunol (2005) 1.03
Uptake of human papillomavirus virus-like particles by dendritic cells is mediated by Fcgamma receptors and contributes to acquisition of T cell immunity. J Immunol (2007) 1.02
The level of secretory leukocyte protease inhibitor is decreased in metastatic head and neck squamous cell carcinoma. Int J Oncol (2011) 1.01
HPV16 E6 and E7 oncoproteins regulate Notch-1 expression and cooperate to induce transformation. J Cell Physiol (2003) 0.99
Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16. J Immunol (2009) 0.98
Sperm protein 17 is expressed in human somatic ciliated epithelia. J Histochem Cytochem (2004) 0.96
Cervical cancer vaccines: recent advances in HPV research. Viral Immunol (2003) 0.95
The cell-mediated immune response to human papillomavirus-induced cervical cancer: implications for immunotherapy. Adv Cancer Res (2002) 0.95
CD4+ T cell matters in tumor immunity. Int Rev Immunol (2003) 0.93
Notch1 regulates chemotaxis and proliferation by controlling the CC-chemokine receptors 5 and 9 in T cell acute lymphoblastic leukaemia. J Pathol (2011) 0.93
A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting. Immunol Rev (2008) 0.92
T-cell receptor tetramer binding or the lack there of does not necessitate antigen reactivity in T-cell receptor transduced T cells. Cancer Immunol Immunother (2005) 0.91
Establishment of an HLA-A*0201 human papillomavirus type 16 tumor model to determine the efficacy of vaccination strategies in HLA-A*0201 transgenic mice. Cancer Res (2002) 0.91
Interferon-gamma reduces melanosomal antigen expression and recognition of melanoma cells by cytotoxic T cells. Am J Pathol (2002) 0.91
Synthetic peptides derived from human antimicrobial peptide ubiquicidin accumulate at sites of infections and eradicate (multi-drug resistant) Staphylococcus aureus in mice. Peptides (2006) 0.91
Expression of LIGHT/TNFSF14 combined with vaccination against human papillomavirus Type 16 E7 induces significant tumor regression. Cancer Res (2010) 0.90
Gamma-radiation upregulates MHC class I/II and ICAM-I molecules in multiple myeloma cell lines and primary tumors. In Vitro Cell Dev Biol Anim (2006) 0.89
Strong synergy between mutant ras and HPV16 E6/E7 in the development of primary tumors. Oncogene (2004) 0.89
Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer. PLoS One (2010) 0.89
Emerging strategies in tumor vaccines. Curr Opin Oncol (2002) 0.89
Lymph node-targeted immunotherapy mediates potent immunity resulting in regression of isolated or metastatic human papillomavirus-transformed tumors. Clin Cancer Res (2009) 0.88
HPV protein/peptide vaccines: from animal models to clinical trials. Front Biosci (2003) 0.88
Rejection of large HPV-16 expressing tumors in aged mice by a single immunization of VacciMax encapsulated CTL/T helper peptides. J Transl Med (2007) 0.87
Disease-stage variance in functional CD4(+) T-cell responses against novel pan-human leukocyte antigen-D region presented human papillomavirus-16 E7 epitopes. Clin Cancer Res (2004) 0.87
Inhibition of Langerhans cell maturation by human papillomavirus type 16: a novel role for the annexin A2 heterotetramer in immune suppression. J Immunol (2014) 0.87
Peptide-based vaccines for cancer immunotherapy. Expert Opin Biol Ther (2004) 0.86
Immunogenicity of an HPV-16 L2 DNA vaccine. Vaccine (2009) 0.86
Therapeutic vaccination for HPV induced cervical cancers. Dis Markers (2007) 0.85
Therapy of established B16-F10 melanoma tumors by a single vaccination of CTL/T helper peptides in VacciMax. J Transl Med (2007) 0.85
Notch-ing from T-cell to B-cell lymphoid malignancies. Cancer Lett (2011) 0.85
Langerhans cells and dendritic cells are cytotoxic towards HPV16 E6 and E7 expressing target cells. Cancer Immunol Immunother (2007) 0.85
Immunological consequences of using three different clinical/laboratory techniques of emulsifying peptide-based vaccines in incomplete Freund's adjuvant. J Transl Med (2006) 0.84
Sperm protein 17 is expressed in the sperm fibrous sheath. J Transl Med (2009) 0.84
Cancer testes antigens in breast cancer: biological role, regulation, and therapeutic applicability. Int Rev Immunol (2012) 0.84
Is sperm protein 17 a useful target for tumor immunotherapy? Blood (2003) 0.84
Cancer testis antigen, ropporin, is a potential target for multiple myeloma immunotherapy. J Immunother (2011) 0.84
Peptide-based vaccines for cancer: realizing their potential. Expert Rev Vaccines (2008) 0.84
Down-regulation of proteasomal subunit MB1 is an independent predictor of improved survival in ovarian cancer. Gynecol Oncol (2009) 0.83
Sperm protein 17 is a suitable target for adoptive T-cell-based immunotherapy in human ovarian cancer. J Immunother (2008) 0.83
Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines. Vaccine (2003) 0.82
Sperm protein 17 expression defines 2 subsets of primary esthesioneuroblastoma. Hum Pathol (2005) 0.82
The efficacy of a DNA vaccine containing inserted and replicated regions of the E7 gene for treatment of HPV-16 induced tumors. Vaccine (2007) 0.82
Advances in immunotherapy of multiple myeloma: from the discovery of tumor-associated antigens to clinical trials. Int Rev Immunol (2007) 0.81
Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. Cancer (2010) 0.81
rAAV/Her-2/neu loading of dendritic cells for a potent cellular-mediated MHC class I restricted immune response against ovarian cancer. Viral Immunol (2008) 0.80
Sperm fibrous sheath proteins: a potential new class of target antigens for use in human therapeutic cancer vaccines. Cancer Immun (2008) 0.79
Progress in the development of immunotherapy of cancer using ex vivo-generated dendritic cells expressing multiple tumor antigen epitopes. Cancer Invest (2004) 0.79
Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition. Cancer Immunol Immunother (2008) 0.79
Recent progress in tumour vaccine development. Expert Opin Investig Drugs (2003) 0.79
Molecular analysis of human papillomavirus virus-like particle activated Langerhans cells in vitro. Methods Mol Biol (2015) 0.79
Human papillomavirus L1L2-E7 virus-like particles partially mature human dendritic cells and elicit E7-specific T-helper responses from patients with cervical intraepithelial neoplasia or cervical cancer in vitro. Hum Immunol (2005) 0.79
Heterologous papillomavirus virus-like particles and human papillomavirus virus-like particle immune complexes activate human Langerhans cells. Vaccine (2005) 0.79
The human lactoferrin-derived peptide hLF1-11 primes monocytes for an enhanced TLR-mediated immune response. Biometals (2010) 0.78
Functional analysis of HPV-like particle-activated Langerhans cells in vitro. Methods Mol Biol (2015) 0.78
Perspective for prophylaxis and treatment of cervical cancer: an immunological approach. Int Rev Immunol (2012) 0.77
A NOD/SCID tumor model for human ovarian cancer that allows tracking of tumor progression through the biomarker Sp17. J Immunol Methods (2007) 0.77
Prevention is better than cure: the case for clinical trials of therapeutic cancer vaccines in the prophylactic setting. Mol Interv (2010) 0.77
A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapies. J Transl Med (2012) 0.76
Comparison of human papillomavirus type 16 L1 chimeric virus-like particles versus L1/L2 chimeric virus-like particles in tumor prevention. Intervirology (2002) 0.76
Forced LIGHT expression in prostate tumors overcomes Treg mediated immunosuppression and synergizes with a prostate tumor therapeutic vaccine by recruiting effector T lymphocytes. Prostate (2014) 0.76
Enhanced tumour growth after DNA vaccination against human papilloma virus E7 oncoprotein: evidence for tumour-induced immune deviation. Vaccine (2003) 0.76
Understanding the cross-talk between ovarian tumors and immune cells: mechanisms for effective immunotherapies. Int Rev Immunol (2011) 0.76
Cure of glioma: a space not yet occupied for the lesion. Cancer Invest (2004) 0.75
Protective CD8+ T-cell responses to cytomegalovirus driven by rAAV/GFP/IE1 loading of dendritic cells. J Transl Med (2008) 0.75
Advances in immunotherapy for prostate cancer. Adv Cancer Res (2003) 0.75
Synopsis of the 4th Walker's Cay Meeting on Cancer Vaccines, 7-10 March 2002. Cancer Immunol Immunother (2002) 0.75
Advances in prophylactic cancer vaccine research. Expert Rev Anticancer Ther (2003) 0.75
In this issue: targeting Human Papilloma Virus-associated disease, from cervical to head and neck carcinoma…and more. Int Rev Immunol (2012) 0.75
Synopsis of the 5th annual Cancer Vaccines and Immunotherapy Colloquium at Walker's Cay. Cancer Immunol Immunother (2003) 0.75